Pivotal single-dose pharmacokinetic study of CCP-08 in patients with cough cold

Trial Profile

Pivotal single-dose pharmacokinetic study of CCP-08 in patients with cough cold

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs CCP 08 (Primary)
  • Indications Common cold; Cough
  • Focus Pharmacokinetics
  • Sponsors Vernalis
  • Most Recent Events

    • 07 Aug 2017 According to a Vernalis media release, the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for CCP-08, FDA identified outstanding items that need to be addressed prior to the resubmission and approval of the NDA.
    • 21 Dec 2016 According to a Vernalis media release, the U.S. Food and Drug Administration has accepted the CCP-08 New Drug Application ("NDA") for full review. The FDA has set a Prescription Drug User Fee Act ("PDUFA") target date for conclusion of its review of 4 August 2017.
    • 13 Apr 2016 According to a Vernalis media release, status changed from planning to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top